Xalud Therapeutics, Inc. — Form D
Xalud Therapeutics, Inc. of CHARLOTTESVILLE, VA, a company, filed a Form D exempt-offering notice with the SEC on 2021-06-02. The offering totals $30.0M, of which $18.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-06-02
- Form: D
- Accession: 0001231919-21-000052
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $30.0M
- Amount sold: $18.2M
- Remaining: $11.8M
- Investors: 12
- Date of first sale: 2021-05-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-401483
Issuer
- Name: Xalud Therapeutics, Inc.
- CIK: 0001646982
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 200 GARRETT STREET, CHARLOTTESVILLE, VA, 22902
- Phone: 434-980-8117
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Stephen Collins | Director | Moraga, CA |
| Paul B Manning | Director | West Chester, PA |
| Diem B Nguyen | Director | West Chester, PA |
| Jayson Rieger | Director | West Chester, PA |
| Sean Stalfort | Director | Charlottesville, VA |
| Stephen Collins | Executive Officer | Moraga, CA |
| Diem B Nguyen | Executive Officer | West Chester, PA |
| Peter Heinecke | Director | San Francisco, CA |
| Linda Watkins | Director | Boulder, CO |
| Raymond Chavez | Director | Alameda, CA |
| Raymond Chavez | Executive Officer | Alameda, CA |
| John Forsayeth | Director | San Francisco, CA |
Other filings by this issuer (2)
More